Retigabine-ezogabine: a new treatment option for bipolar disorder?
Bipolar Disord. 2019 Feb 27;:
Authors: Mazza M, Marano G, Janiri L
Abstract
The M-channels (i.e., voltage-gated potassium channels formed by KCNQ2, KCNQ3 and KCNQ 5) has emerged as a promising target for treating bipolar disorder. M- Kv7 channel activators have shown to decrease neuronal excitability and might potentially treat neuronal hyperexcitability disorders like epilepsy and mania. Recent data demonstrate that voltage-gated neuronal Kv7/KCNQ/M-current modulates the excitability and synaptic transmission of prefrontal cortex neurons, suggesting that pharmacological modulation of M-current in the prefrontal cortex may exert beneficial effects on cognitive deficits implicated in the pathophysiology of many neuropsychiatric disorders. This article is protected by copyright. All rights reserved.
PMID: 30811779 [PubMed - as supplied by publisher]
from A via a.sfakia on Inoreader https://ift.tt/2GO0eYZ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,